Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

J&J’s Darzalex Could Gain Another Breakthrough Tag with New Study Data

By Ryan Bushey | October 10, 2016

The good news continues rolling in for Johnson & Johnson.

New study results indicate the drug Darzalex could be a valid treatment regimen for multiple myeloma patients at all stages of the diseases, reported FiercePharma.

Investigators running this trial compared the Darzalex combination therapy against Celgene’s Revlimid and dexamethasone in a trial with 569 patients.

Results showed the Darzalex cocktail was the superior alternative for treatment leading to complete response rate of 43.1 percent in patients participating in this trial. By contrast, volunteers taking Revlimid and dexamethasone experience a 19.2 percent response rate.

Furthermore, Darzalex, “also cut the risk of disease progression an impressive 63 percent compared with the two-drug approach,” according to FiercePharma.

J&J gained a breakthrough designation for the Darzalex combinations in July 2016 for patients who have received at least one prior therapy. Positive data like this could support the company’s case for another label expanding the patient pool for people who tend to stay on these therapies for longer periods of time.

Both authors of this study, Dr. S. Vincent Rajkumar and Dr. Robert A. Kyle, wrote a commentary in the New England Journal of Medicine saying that this drug was a “landmark advance” and could become the new standard treatment of care for multiple myeloma within the next few years.

This announcement comes on the heels of J&J’s next-gen psoriasis drug beating out Humira in a late-stage study setting the stage for a competition against AbbVie’s prized product.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50